The co‐formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta‐analysis of phase III studies in patients with type 2 diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The co‐formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta‐analysis of phase III studies in patients with type 2 diabetes

Published:2018-03-25 Issue:7 Volume:20 Page:1585-1592
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Haluzík Martin¹^ORCID,Fulcher Greg²,Pieber Thomas R.³,Bardtrum Lars⁴,Tutkunkardas Deniz⁴,Rodbard Helena W.⁵^ORCID

Affiliation:

1. Institute for Clinical and Experimental Medicine and Charles University Prague Czech Republic

2. Royal North Shore Hospital University of Sydney Sydney Australia

3. Medical University of Graz Graz Austria

4. Novo Nordisk A/S Søborg Denmark

5. Endocrine and Metabolic Consultants Rockville Maryland

Funder

The phase III programme for insulin degludec/insulin aspart was funded by Novo Nordisk A/S.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13261

Reference40 articles.

1. Five Stages of Evolving Beta-Cell Dysfunction During Progression to Diabetes

2. U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease

3. Non-adherence to self-care practices & medication and health related quality of life among patients with type 2 diabetes: a cross-sectional study

4. Adherence to Therapies in Patients with Type 2 Diabetes

5. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Initiation or switch to insulin degludec/insulin aspart in adults with type 2 diabetes in India: Results from a prospective, non-interventional, real-world study;Journal of Family Medicine and Primary Care;2024-09

2. Initiating or switching to insulin degludec/insulin aspart in a real‐world population of adults with type 2 diabetes in Australia: results from a prospective, non‐interventional study;Internal Medicine Journal;2024-08-22

3. Improvement in Glycemic Indices and Point in Range by Addition or Switch to IDegAsp–Real-World Evidence;Journal of Diabetology;2024-07

4. Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes in Malaysia: Results from a Prospective, Non-Interventional Real-World Study;Journal of the ASEAN Federation of Endocrine Societies;2023-05-18

5. Evaluation of the efficiency of insulin degludec/insulin aspart therapy in controlling hyperglycemia and hypoglycemia in patients with type 2 diabetes mellitus: a real-life experience;International Journal of Diabetes in Developing Countries;2022-11-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3